Cancer and Control of Genomic Integrity (CANGENIN)













COST is an intergovernmental framework for European Co-operation in the field of Scientific and Technical Research. COST networks are called Actions.

The COST Action BM0703 – Cancer and Control of Genomic Integrity – or CANGENIN for short was approved on November 16th, 2007 (Memorandum of Understanding). CANGENIN started on May 21st, 2008, and the duration is 4 years. The current member countries of CANGENIN are listed here.

The main objective of CANGENIN is to advance our knowledge on mechanisms that protect healthy cells from transforming into cancer cells.  CANGENIN is providing an interaction platform for research focused on genomic integrity and epigenetics and their dysregulation in cancer. It will link researchers in basic sciences with approaches in translational cancer research.

Scientific focus of CANGENIN:

  • Cellular DNA damage signalling pathways
  • Chromatin modifications and transcriptional control
  • Cancer epigenetics
  • Cancer model systems and translational research

Annual meetings, Short-Term Scientific Missions/exchange visits and training schools are important integrative elements of CANGENIN in promoting scientific interactions and training for young scientists.

CANGENIN is implemented through the Management Committee (MC) and the Working Groups (WGs).